公开(公告)号：WO2017048950A1

公开(公告)日：2017-03-23

申请号：PCT/US2016/051934

申请日：2016-09-15

Applicant: ASSEMBLY BIOSCIENCES, INC. ,  INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： TURNER, William ,  ARNOLD, Lee, Daniel ,  MAAG, Hans ,  LI, Leping ,  BURES, Mark ,  HAYDAR, Simon ,  FRANCIS, Samson

IPC: A01N57/00

CPC classification number: A61K45/06 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

Abstract translation: 本公开部分地提供对乙型肝炎病毒Cp具有变构效应子特性的化合物。 本文还提供了治疗病毒感染（例如乙型肝炎）的方法，其包括向有需要的患者施用所公开的化合物。

公开(公告)号：WO2017048962A1

公开(公告)日：2017-03-23

申请号：PCT/US2016/051949

申请日：2016-09-15

Applicant: ASSEMBLY BIOSCIENCES, INC. ,  INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： TURNER, William ,  MAAG, Hans ,  FRANCIS, Samson

IPC: A01N57/00

CPC classification number: A61K45/06 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

公开(公告)号：WO2015057945A1

公开(公告)日：2015-04-23

申请号：PCT/US2014/060869

申请日：2014-10-16

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

Inventor： ZLOTNICK, Adam ,  LI, Lichun ,  TURNER, William Jr. ,  FRANCIS, Samson

IPC: A61K31/535 ,  A61K31/497 ,  C07D413/00

CPC classification number: A61K31/506 ,  C07D239/47 ,  C07D239/48

Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Abstract translation: 公开了具有针对乙型肝炎病毒（HBV）感染的治疗作用的新型组装效应物化合物。 本文所述的组装效应分子可导致病毒组装有缺陷，也可能影响与慢性HBV感染有关的其他病毒活性。 还公开了合成所公开的化合物的方法，通过施用所公开的化合物治疗HBV的方法，以及这些化合物在制备针对HBV的药物中的用途。